GoodRx (NASDAQ:GDRX) Trading Up 7.9% – Should You Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price traded up 7.9% during trading on Tuesday . The company traded as high as $2.37 and last traded at $2.3850. 747,396 shares traded hands during trading, a decline of 75% from the average session volume of 2,998,346 shares. The stock had previously closed at $2.21.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GoodRx in a research note on Tuesday, December 23rd. Morgan Stanley decreased their target price on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Barclays started coverage on GoodRx in a report on Monday, December 8th. They issued an “underweight” rating and a $3.00 price target for the company. TD Cowen decreased their price objective on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Finally, Wall Street Zen lowered GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.73.

GoodRx Stock Up 7.0%

The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $802.75 million, a price-to-earnings ratio of 26.28, a price-to-earnings-growth ratio of 0.93 and a beta of 1.50. The firm has a 50 day moving average price of $2.65 and a two-hundred day moving average price of $3.46.

Institutional Trading of GoodRx

Large investors have recently added to or reduced their stakes in the stock. Meridian Wealth Management LLC bought a new stake in GoodRx during the 4th quarter valued at $29,000. Quarry LP acquired a new position in shares of GoodRx during the third quarter valued at $33,000. Boothbay Fund Management LLC bought a new stake in shares of GoodRx during the third quarter valued at about $43,000. Shay Capital LLC acquired a new stake in GoodRx in the third quarter worth about $47,000. Finally, Hirtle Callaghan & Co LLC grew its position in GoodRx by 60.3% in the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after buying an additional 6,869 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.